- Trials with a EudraCT protocol (30)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (3)
30 result(s) found for: PAF.
Displaying page 1 of 2.
EudraCT Number: 2006-006863-22 | Sponsor Protocol Number: 2006/CD/013 | Start Date*: 2007-09-24 | |||||||||||
Sponsor Name:University Hospital of South Manchester NHS Foundation Trust | |||||||||||||
Full Title: Role of Poly Unsaturated Fatty Acids (PUFAs) in the management of Paroxysmal Atrial Fibrillation (PAF) | |||||||||||||
Medical condition: Paroxysmal Atrial Fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001382-15 | Sponsor Protocol Number: ATI-2042-CLN-205 | Start Date*: 2007-09-20 | |||||||||||
Sponsor Name:ARYx Therapeutics | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of ATI-2042 in Patients with Paroxysmal Atrial Fibrillation and Pacemakers with Atrial Fibrillation Data Logging Capabilities | |||||||||||||
Medical condition: The trial is to investigate the efficacy of the new drug ATI-2042 to reduce the atrial tachyarrhythmia burden in patients with paroxysmal atrial fabrilation. ATI-2042 is designed to act like Amioda... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022947-39 | Sponsor Protocol Number: CV203-010 | Start Date*: 2011-03-18 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: Randomized, Double-Blind, Placebo-Controlled, 4-Way Crossover Study to Evaluate the Safety, Tolerability and Effect on Atrial Fibrillation Burden of BMS-914392 in Patients with Paroxysmal Atrial Fi... | ||||||||||||||||||
Medical condition: Atrial Fibrillation | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-000695-34 | Sponsor Protocol Number: Verna-Ibu-AF_1.0 | Start Date*: 2011-07-22 | |||||||||||
Sponsor Name:Medizinische Universität Wien, Univ.-Klinik für Notfallmedizin | |||||||||||||
Full Title: Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation | |||||||||||||
Medical condition: recent-onset atrial fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001134-42 | Sponsor Protocol Number: GS-US-291-0102 | Start Date*: 2012-05-22 | |||||||||||
Sponsor Name:Gilead Sciences, Inc | |||||||||||||
Full Title: A phase 2, proof of concept, randomised, placebo-controlled, parallel group study to evaluate the effect of ranolazine and dronedarone when given alone and in combination on atrial fibrillation bur... | |||||||||||||
Medical condition: Paroxysmal Atrial Fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004456-38 | Sponsor Protocol Number: XEN-D0103-CL-05 | Start Date*: 2014-04-11 | |||||||||||
Sponsor Name:Xention Limited | |||||||||||||
Full Title: A double blind, randomised, placebo-controlled, crossover study assessing the use of XEN D0103 in patients with paroxysmal atrial fibrillation and implanted pacemakers allowing continuous beat-to-b... | |||||||||||||
Medical condition: Paroxysmal atrial fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003641-95 | Sponsor Protocol Number: SELECTI-CARFAP | Start Date*: 2015-02-13 | |||||||||||
Sponsor Name:Nicasio Pérez Castellano | |||||||||||||
Full Title: Randomized clinical trial to study effective pharmacological cardioversion of paroxysmal atrial fibrillation by blocking ionic currents atrioselectivas by treatment with vernakalant vs Flecainide | |||||||||||||
Medical condition: Atrial fibrillation paroxysmal | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004094-93 | Sponsor Protocol Number: PAFCUTIII | Start Date*: 2012-04-19 | |||||||||||
Sponsor Name:Allergie-Centrum Charité | |||||||||||||
Full Title: Double-blind, three-way cross-over, placebo controlled study to assess the efficacy, safety and mechanisms of treatment with rupatadine 20 and 40mg in cold contact urticaria (CCU) | |||||||||||||
Medical condition: Cold contact urticaria | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002855-26 | Sponsor Protocol Number: Droxidopa-301 | Start Date*: 2008-10-01 |
Sponsor Name:Chelsea Therapeutics Inc | ||
Full Title: A Multi-Centre, Double-Blind, Placebo-Controlled, Parallel-Group Induction-Design Study to assess the Clinical Effect of Droxidopa in Subjects with Primary Autonomic Failure, Dopamine Beta Hydroxyl... | ||
Medical condition: Symptomatic neurogenic orthostatic hypotension (NOH) in patients with Primary Autonomic Failure (Pharmacodynamic, MSA and PAF), DBH deficiency and Non-Diabetic Neuropathy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) AT (Completed) CZ (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-002996-18 | Sponsor Protocol Number: ATI-2042-CLN-08 | Start Date*: 2005-03-10 | |||||||||||
Sponsor Name:ARYx Therapeutics Limited | |||||||||||||
Full Title: A Phase 2 Pilot Study of the Efficacy of ATI-2042 in subjects with Paroxysmal Atrial Fibrillation and Pacemakers | |||||||||||||
Medical condition: Paroxysmal Atrial Fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003289-15 | Sponsor Protocol Number: 0169 | Start Date*: 2019-05-08 |
Sponsor Name:Theravance Biopharma Ireland Limited | ||
Full Title: A Phase 3, 4-week, Multicenter, Randomized, Double-blind,Placebo-controlled,Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Auton... | ||
Medical condition: Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) EE (Completed) DE (Completed) DK (Completed) AT (Completed) HU (Completed) PL (Completed) ES (Ongoing) BG (Completed) PT (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-003941-41 | Sponsor Protocol Number: 0170 | Start Date*: 2019-08-09 |
Sponsor Name:Theravance Biopharma Ireland Limited | ||
Full Title: A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure | ||
Medical condition: Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) EE (Prematurely Ended) PL (Completed) ES (Prematurely Ended) AT (Prematurely Ended) DK (Prematurely Ended) BG (Prematurely Ended) HU (Completed) PT (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2014-002333-63 | Sponsor Protocol Number: CL2-066913-002 | Start Date*: 2014-11-12 | |||||||||||
Sponsor Name:Institut de Recherches Internationales Servier | |||||||||||||
Full Title: A randomized, double blind, placebo-controlled, parallel, international multicenter study assessing the efficacy of S066913 in patients with paroxysmal atrial fibrillation Double-blind, Internati... | |||||||||||||
Medical condition: Paroxysmal Atrial Fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) SK (Prematurely Ended) SE (Prematurely Ended) DK (Prematurely Ended) NL (Completed) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005673-60 | Sponsor Protocol Number: Droxidopa-302 | Start Date*: 2009-04-22 |
Sponsor Name:Chelsea Therapeutics Inc | ||
Full Title: A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP WITHDRAWAL-DESIGN STUDY TO ASSESS THE CLINICAL EFFECT OF DROXIDOPA IN SUBJECTS WITH PRIMARY AUTONOMIC FAILURE, DOPAMINE ... | ||
Medical condition: Symptomatic neurogenic orthostatic hypotension (NOH) in patients with Primary Autonomic Failure (PD, MSA and PAF), DBH deficiency and Non-Diabetic Neuropathy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-000797-30 | Sponsor Protocol Number: SPI-IIT-002 | Start Date*: 2013-10-08 | |||||||||||||||||||||
Sponsor Name:Department of Medical Research, Odense University Hospital, Svendborg Hospital | |||||||||||||||||||||||
Full Title: Inhibition of aldosterone to diminish diffuse myocardial fibrosis in atrial fibrillation | |||||||||||||||||||||||
Medical condition: Paroxysmal and persistent atrial fibrillation | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-002979-17 | Sponsor Protocol Number: K620 | Start Date*: 2018-12-17 | |||||||||||||||||||||
Sponsor Name:Ruprecht-Karls University Heidelberg Medical Faculty, University Hospital | |||||||||||||||||||||||
Full Title: Use of doxapram as a new antiarrhythmic drug for a specific therapy of atrial fibrillation | |||||||||||||||||||||||
Medical condition: Paroxysmal or persistent, non-valvular, atrial fibrillation | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016880-13 | Sponsor Protocol Number: ITU version1 19/10/2009 | Start Date*: 2011-03-11 |
Sponsor Name:UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST | ||
Full Title: RANDOMIZED CONTROLLED TRIAL OF THE EFFECTS OF PARENTERAL FISH OIL EMULSION IN CRITICALLY ILL SEPTIC PATIENTS IN THE INTENSIVE CARE UNIT | ||
Medical condition: Sepsis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-002442-45 | Sponsor Protocol Number: AXAFA-AFNET5 | Start Date*: Information not available in EudraCT | ||||||||||||||||||||||||||
Sponsor Name:Kompetenznetz Vorhofflimmern e.V. [Atrial Fibrillation NETwork (AFNET)] | ||||||||||||||||||||||||||||
Full Title: Anticoagulation using the direct factor Xa inhibitor apixaban during Atrial Fibrillation catheter Ablation: Comparison to vitamin K antagonist therapy. | ||||||||||||||||||||||||||||
Medical condition: Atrial fibrillation catheter ablation | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Completed) BE (Completed) DK (Completed) GB (Completed) NL (Completed) ES (Completed) AT (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-005701-22 | Sponsor Protocol Number: Droxidopa-303 | Start Date*: 2009-04-13 |
Sponsor Name:Chelsea Therapeutics Inc | ||
Full Title: A MULTI-CENTER, OPEN-LABEL STUDY, WITH A TWO WEEK RANDOMIZED, PLACEBO-CONTROLLED, WITHDRAWAL PERIOD, TO ASSESS THE LONG-TERM SAFETY AND CLINICAL BENEFIT OF DROXIDOPA IN SUBJECTS WITH PRIMARY AUTONO... | ||
Medical condition: Symptomatic neurogenic orthostatic hypotension (NOH) in patients with Primary Autonomic Failure (PD, MSA and PAF), DBH deficiency and Non-Diabetic Neuropathy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) PL (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-000094-76 | Sponsor Protocol Number: FLE-002 | Start Date*: 2018-05-02 | |||||||||||
Sponsor Name:InCarda Therapeutics, Inc. | |||||||||||||
Full Title: A prospective, randomized, multicenter study of flecainide acetate oral inhalation solution in single and repeat dose regimens for acute conversion to sinus rhythm (SR) in subjects with recent onse... | |||||||||||||
Medical condition: Acute conversion to sinus rhythm (SR) in subjects with recent onset of symptomatic paroxysmal atrial fibrillation (AF). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
